ストックスクリーナーアプリを入手
23.06
6.60%
-1.63
前日終値:
$24.69
開ける：
$24.86
24時間の取引高:
1.55M
Relative Volume:
0.83
時価総額：
$2.39B
収益：
$71.78M
当期純損益:
$-295.28M
株価収益率:
-7.2982
EPS:
-3.1597
ネットキャッシュフロー:
$-271.85M
1週間 パフォーマンス:
-3.80%
1か月 パフォーマンス:
+50.72%
6か月 パフォーマンス:
+19.48%
1年 パフォーマンス:
+82.00%
1日の値動き範囲:
$22.33
$24.86
1週間の範囲:
$22.33
$24.95
52週間の値動き範囲:
$8.195
$24.95
Nurix Therapeutics Inc Stock (NRIX) Company Profile
名前
Nurix Therapeutics Inc
セクター
電話
(415) 660-5320
住所
1600 SIERRA POINT PKWY, BRISBANE
Compare NRIX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
23.06 | 2.39B | 71.78M | -295.28M | -271.85M | -3.1597 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-08 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-24 | 再開されました | Truist | Buy |
| 2025-10-21 | 開始されました | Mizuho | Outperform |
| 2025-03-17 | 開始されました | Leerink Partners | Market Perform |
| 2024-12-10 | 開始されました | BTIG Research | Buy |
| 2024-12-06 | 開始されました | BMO Capital Markets | Outperform |
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-10-11 | 開始されました | Jefferies | Buy |
| 2024-09-06 | 再開されました | Robert W. Baird | Outperform |
| 2024-07-31 | 開始されました | Truist | Buy |
| 2023-06-26 | 再開されました | Oppenheimer | Outperform |
| 2023-03-09 | 開始されました | Barclays | Overweight |
| 2023-02-28 | 開始されました | Oppenheimer | Outperform |
| 2022-10-11 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-05-31 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-02-10 | 開始されました | Wells Fargo | Equal Weight |
| 2021-12-29 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-14 | 開始されました | SVB Leerink | Outperform |
| 2021-06-04 | 再開されました | Robert W. Baird | Outperform |
| 2021-04-30 | 再開されました | Piper Sandler | Overweight |
| 2021-04-30 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-04-14 | 開始されました | Berenberg | Buy |
| 2020-11-19 | 開始されました | Robert W. Baird | Outperform |
| 2020-08-18 | 開始されました | JP Morgan | Overweight |
| 2020-08-18 | 開始されました | Needham | Buy |
| 2020-08-18 | 開始されました | Piper Sandler | Overweight |
| 2020-08-18 | 開始されました | Stifel | Buy |
すべてを表示
Nurix Therapeutics Inc (NRIX) 最新ニュース
NRIX Maintained by HC Wainwright & Co. -- Price Target Raised to $34 - GuruFocus
Enterprise value to EBITDA forward of Nurix Therapeutics, Inc. – NASDAQ:NRIX - TradingView
Nurix Therapeutics, Inc. Stock 12‑Month Price Target Raised to $32.5, Implies 32% Upside - TradingView
NRIX Maintained by Truist Securities -- Price Target Raised to $34.00 - GuruFocus
RBC Capital Initiates Nurix Therapeutics(NRIX.US) With Buy Rating, Announces Target Price $33 - Moomoo
A Quick Look at Today's Ratings for Nurix Therapeutics(NRIX.US), With a Forecast Between $28 to $40 - Moomoo
Nurix stock price target raised to $34 by H.C. Wainwright By Investing.com - Investing.com India
Mizuho raises Nurix stock price target to $34 on Roche deal By Investing.com - Investing.com South Africa
Nurix stock price target raised to $34 by H.C. Wainwright - Investing.com UK
Baird reiterates Nurix stock Outperform rating at $33 target By Investing.com - Investing.com India
Nurix Therapeutics, Inc. Stock 12‑Month Price Target Raised to $32.25, Implies 31% Upside - TradingView
Russell Growth Index Additions Could Be A Game Changer For Nurix Therapeutics (NRIX) - Sahm
Nurix Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
NRIX Reiterated by Needham -- Price Target Maintained at $34 - GuruFocus
NRIX Maintained by Stifel -- Price Target Raised to $40 - GuruFocus
NRIX Maintained by RBC Capital -- Price Target Raised to $33 - GuruFocus
Nurix Therapeutics (NASDAQ:NRIX) Shares Down 8.6% After Earnings Miss - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Price Target Raised to $40.00 - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Price Target Raised to $33.00 at Royal Bank Of Canada - MarketBeat
NRIX Reiterates by BTIG -- Price Target Maintained at $32 - GuruFocus
BTIG Research Reaffirms "Buy" Rating for Nurix Therapeutics (NASDAQ:NRIX) - MarketBeat
Needham & Company LLC Reiterates Buy Rating for Nurix Therapeutics (NASDAQ:NRIX) - MarketBeat
RBC Capital Raises Nurix Therapeutics Price Target to $33 From $30, Maintains Outperform Speculative Risk Rating - marketscreener.com
Nurix Therapeutics Reports Q2 Loss, Revenue Falls Short Of Expectations - Bitcoin World
Nurix Therapeutics, Inc. (NRIX) reports Q2 loss, lags revenue estimates - FXStreet
NRIX SWOT Analysis: Key Insights from 10-Q Filing - GuruFocus
Nurix Therapeutics, Inc. (NRIX) Q2 2026 Earnings: Financial Results, Risk Factors, and Forward-Looking Statements Overview - Minichart
Nurix Therapeutics, Inc. Files Form 8-K Announcing July 2026 Press Release and Nasdaq Listing Details - Minichart
Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Nurix (NRIX) Reports Q2 Revenue Miss, Highlights Roche Collabora - GuruFocus
Is Nurix Therapeutics Inc (NRIX) Facing Valuation Concerns After - GuruFocus
Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Globe and Mail
Enterprise value to EBIT forward of Nurix Therapeutics, Inc. – NASDAQ:NRIX - TradingView
Nurix Therapeutics Expects to Receive $700 M Upfront Payment From Roche in 3Q - Moomoo
Nurix Therapeutics (NASDAQ:NRIX) Releases Quarterly Earnings Results - MarketBeat
Nurix Therapeutics (NASDAQ: NRIX) widens loss but secures $700M Roche bexobrutideg collaboration - Stock Titan
Nurix Therapeutics Q2 revenue falls sharply, net loss widens; strikes up to $2.3 bln collab with Roche - TradingView
Earnings Flash (NRIX) Nurix Therapeutics, Inc. Reports Q2 Revenue $9.0M, vs. FactSet Est of $15.3M - marketscreener.com
Nurix Therapeutics (NASDAQ:NRIX) Hits New 1-Year HighWhat's Next? - MarketBeat
Nurix Therapeutics stock hits 52-week high at $24.93 By Investing.com - Investing.com South Africa
Nurix Therapeutics stock hits 52-week high at $24.93 - Investing.com
Precision Trading with Nurix Therapeutics Inc. (NRIX) Risk Zones - Stock Traders Daily
Price to sales forward of Nurix Therapeutics, Inc. – NASDAQ:NRIX - TradingView
Nurix Therapeutics earnings loom: Roche deal impact in focus By Investing.com - Investing.com South Africa
Nurix Therapeutics earnings loom: Roche deal impact in focus - Investing.com
Nurix stock up 29% in a month: Here's what you should know - MSN
Nurix Therapeutics patents new SMARCA2-targeting PROTACs - BioWorld News
NRIX Q2'26 Earnings: EPS estimate is (0.72) USD - TradingView
Nurix Therapeutics outlines its pipeline strategy - Ad-hoc-news.de
Roche collaborates with Nurix Therapeutics to develop BTK degrader bexobrutideg for cancer and immune diseases - Select Science
Price to earnings forward of Nurix Therapeutics, Inc. – NASDAQ:NRIX - TradingView
Nurix Therapeutics Inc (NRIX) 財務データ
収益
当期純利益
現金流量
EPS
Nurix Therapeutics Inc (NRIX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Ring Christine | Chief Legal Officer |
Jul 02 '26 |
Sale |
23.56 |
11,008 |
259,366 |
13,579 |
2.64%
大文字化:
|
ボリューム (24 時間):